LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 632

Search options

  1. Article ; Online: Global Health Burden of Venous Thromboembolism.

    Wendelboe, Aaron / Weitz, Jeffrey I

    Arteriosclerosis, thrombosis, and vascular biology

    2024  Volume 44, Issue 5, Page(s) 1007–1011

    MeSH term(s) Humans ; Venous Thromboembolism/epidemiology ; Venous Thromboembolism/diagnosis ; Global Health ; Risk Factors ; Risk Assessment ; Global Burden of Disease
    Language English
    Publishing date 2024-04-24
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
    ZDB-ID 1221433-4
    ISSN 1524-4636 ; 1079-5642
    ISSN (online) 1524-4636
    ISSN 1079-5642
    DOI 10.1161/ATVBAHA.124.320151
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1705: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Book: Hematology

    Benz, Edward J. / Silberstein, Leslie E. / Heslop, Helen E. / Weitz, Jeffrey I. / Anastasi, John / Salama, Mohamed E. / Hoffman, Ronald

    basic principles and practice

    (ExpertConsult.com)

    2018  

    Author's details [edited by] Ronald Hoffman, Edward J. Benz, Jr., Leslie E. Silberstein, Helen E. Heslop, Jeffrey I. Weitz, John Anastasi, Mohamed E. Salama
    Series title ExpertConsult.com
    Keywords Hematologic Diseases / diagnosis ; Hematologic Diseases / therapy ; Blood Physiological Phenomena
    Language English
    Size xxx, 2374 Seiten, Illustrationen
    Edition Seventh edition
    Publisher Elsevier
    Publishing place Philadelphia, PA
    Publishing country United States
    Document type Book
    Note Zugang zu Online-Ausgabe über Code und QR-Code
    HBZ-ID HT019486278
    ISBN 978-0-323-35762-3 ; 9780323509718 ; 0-323-35762-8 ; 0323509711
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    2018 A 15 available for loan (reading room) Lesesaal EG
    Zugang zu Online-Ausgabe über Code und QR-Code aus lizenzrechtlichen Gründen nicht verfügbar
    2018 A 1234 available for loan (reading room) Lesesaal EG
    Zugang zu Online-Ausgabe über Code und QR-Code aus lizenzrechtlichen Gründen nicht verfügbar

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Direct Oral Anticoagulants in the Very Elderly.

    Eikelboom, John W / Weitz, Jeffrey I

    Thrombosis and haemostasis

    2023  Volume 123, Issue 4, Page(s) 377–379

    MeSH term(s) Humans ; Aged ; Anticoagulants/adverse effects ; Warfarin/therapeutic use ; Administration, Oral ; Atrial Fibrillation/drug therapy
    Chemical Substances Anticoagulants ; Warfarin (5Q7ZVV76EI)
    Language English
    Publishing date 2023-01-29
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 518294-3
    ISSN 2567-689X ; 0340-6245
    ISSN (online) 2567-689X
    ISSN 0340-6245
    DOI 10.1055/a-2021-8910
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.192: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 433: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Book: Meeting the challenges in the management of venous thromboembolism

    Weitz, Jeffrey I.

    oral direct thrombin inhibition: a new concept ; a seminar-in-print

    (Drugs ; 64, Suppl. 1)

    2004  

    Author's details guest ed. J. Weitz
    Series title Drugs ; 64, Suppl. 1
    Collection
    Language English
    Size 52 S. : graph. Darst.
    Publisher Adis Internat
    Publishing place Auckland u.a.
    Publishing country New Zealand
    Document type Book
    HBZ-ID HT014138421
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Zs A 762 -64,Suppl.1- not available for loan Zeitschriften-Lesesaal

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: New Therapeutic Targets for the Prevention and Treatment of Venous Thromboembolism With a Focus on Factor XI Inhibitors.

    Chan, Noel C / Weitz, Jeffrey I

    Arteriosclerosis, thrombosis, and vascular biology

    2023  Volume 43, Issue 10, Page(s) 1755–1763

    Abstract: FXI (factor XI) and FXII (factor XII) have emerged as targets for new anticoagulants that have the potential to be both more efficacious and safer than the currently available direct oral anticoagulants for the prevention and treatment of venous ... ...

    Abstract FXI (factor XI) and FXII (factor XII) have emerged as targets for new anticoagulants that have the potential to be both more efficacious and safer than the currently available direct oral anticoagulants for the prevention and treatment of venous thromboembolism. In this review, we discuss the role of FXI and FXII in the pathogenesis of venous thromboembolism, explain why FXI is a better target, and explain why FXI inhibitors have potential advantages over currently available anticoagulants. Finally, we describe the FXI inhibitors under development and discuss their potential to address unmet needs in venous thromboembolism management.
    MeSH term(s) Humans ; Factor XI ; Blood Coagulation ; Thrombosis/drug therapy ; Venous Thromboembolism/drug therapy ; Venous Thromboembolism/prevention & control ; Anticoagulants/adverse effects ; Factor XII
    Chemical Substances Factor XI (9013-55-2) ; Anticoagulants ; Factor XII (9001-30-3)
    Language English
    Publishing date 2023-08-31
    Publishing country United States
    Document type Review ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1221433-4
    ISSN 1524-4636 ; 1079-5642
    ISSN (online) 1524-4636
    ISSN 1079-5642
    DOI 10.1161/ATVBAHA.123.318781
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1705: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: News at XI: moving beyond factor Xa inhibitors.

    Fredenburgh, James C / Weitz, Jeffrey I

    Journal of thrombosis and haemostasis : JTH

    2023  Volume 21, Issue 7, Page(s) 1692–1702

    Abstract: Oral anticoagulants are a mainstay for the prevention and treatment of arterial and venous thrombosis. Direct oral anticoagulants (DOACs) have replaced vitamin K antagonists for many indications. Currently available DOACs include dabigatran, which ... ...

    Abstract Oral anticoagulants are a mainstay for the prevention and treatment of arterial and venous thrombosis. Direct oral anticoagulants (DOACs) have replaced vitamin K antagonists for many indications. Currently available DOACs include dabigatran, which inhibits thrombin, and apixaban, edoxaban, and rivaroxaban, which inhibit factor (F) Xa. A new class of DOACs is under development. These new DOACs, which include asundexian and milvexian, inhibit FXIa, which is positioned in the intrinsic pathway of coagulation. Anticoagulants that target FXIa have the potential to be safer than the current DOACs because there is emerging evidence that FXI is essential for thrombosis but mostly dispensable for hemostasis. In addition to the oral inhibitors of FXIa, parenteral inhibitors are also under development. These include fesomersen, an antisense oligonucleotide that reduces the hepatic synthesis of FXI; abelacimab, an antibody that binds to FXI and blocks its activation; and osocimab, an FXIa inhibitory antibody. Focusing on these new agents, this article describes the unmet needs in oral anticoagulation therapy, explains why FXI is a promising target for new oral anticoagulants, reviews phase 2 clinical data on new agents, describes ongoing phase 3 trials, and provides a perspective on the opportunities and challenges for FXI inhibitors.
    MeSH term(s) Humans ; Administration, Oral ; Anticoagulants/chemistry ; Anticoagulants/therapeutic use ; Dabigatran ; Factor Xa Inhibitors/chemistry ; Factor Xa Inhibitors/therapeutic use ; Factor XI ; Rivaroxaban/therapeutic use
    Chemical Substances Anticoagulants ; Dabigatran (I0VM4M70GC) ; Factor Xa Inhibitors ; Factor XI (9013-55-2) ; milvexian (0W79NDQ608) ; Rivaroxaban (9NDF7JZ4M3)
    Language English
    Publishing date 2023-04-26
    Publishing country England
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 2112661-6
    ISSN 1538-7836 ; 1538-7933
    ISSN (online) 1538-7836
    ISSN 1538-7933
    DOI 10.1016/j.jtha.2023.04.021
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5805: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 295: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Warfarin faring better: vitamin K antagonists beat rivaroxaban and apixaban in the INVICTUS and PROACT Xa trials.

    Eikelboom, John W / Weitz, Jeffrey I

    Journal of thrombosis and haemostasis : JTH

    2023  Volume 21, Issue 11, Page(s) 3067–3071

    Abstract: Although guidelines give preference to direct oral anticoagulants (DOACs) over vitamin K antagonists (VKAs) for stroke prevention in most patients with atrial fibrillation (AF), DOACs are not recommended in those with rheumatic heart disease or ... ...

    Abstract Although guidelines give preference to direct oral anticoagulants (DOACs) over vitamin K antagonists (VKAs) for stroke prevention in most patients with atrial fibrillation (AF), DOACs are not recommended in those with rheumatic heart disease or mechanical heart valves. The results of the INVICTUS trial (Investigation of Rheumatic AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies), which compared rivaroxaban with a VKA in patients with rheumatic heart disease-associated AF, and the PROACT Xa trial (A Trial to Determine if Participants with an On-X Aortic Valve Can be Maintained Safely on Apixaban), which compared apixaban with warfarin in patients with an On-X valve in the aortic position, support the use of VKAs for these indications. In this paper, we review the results of these trials, provide perspective on why VKAs were superior to DOACs, and discuss future directions for anticoagulation in these disorders.
    MeSH term(s) Humans ; Warfarin/adverse effects ; Rivaroxaban/adverse effects ; Rheumatic Heart Disease/complications ; Rheumatic Heart Disease/drug therapy ; Anticoagulants/adverse effects ; Pyridones/therapeutic use ; Atrial Fibrillation/diagnosis ; Atrial Fibrillation/drug therapy ; Atrial Fibrillation/complications ; Vitamin K ; Administration, Oral ; Fibrinolytic Agents/therapeutic use ; Stroke/drug therapy ; Stroke/prevention & control ; Stroke/complications ; Dabigatran/therapeutic use
    Chemical Substances Warfarin (5Q7ZVV76EI) ; Rivaroxaban (9NDF7JZ4M3) ; apixaban (3Z9Y7UWC1J) ; Anticoagulants ; Pyridones ; Vitamin K (12001-79-5) ; Fibrinolytic Agents ; Dabigatran (I0VM4M70GC)
    Language English
    Publishing date 2023-07-08
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2112661-6
    ISSN 1538-7836 ; 1538-7933
    ISSN (online) 1538-7836
    ISSN 1538-7933
    DOI 10.1016/j.jtha.2023.06.036
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5805: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 295: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: ISTH Biennial Impact Report: Looking back and looking forward.

    Weitz, Jeffrey I / Peyvandi, Flora

    Journal of thrombosis and haemostasis : JTH

    2022  Volume 20, Issue 7, Page(s) 1515–1517

    Language English
    Publishing date 2022-07-11
    Publishing country England
    Document type Editorial
    ZDB-ID 2112661-6
    ISSN 1538-7836 ; 1538-7933
    ISSN (online) 1538-7836
    ISSN 1538-7933
    DOI 10.1111/jth.15749
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5805: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 295: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Ciraparantag as a potential universal anticoagulant reversal agent.

    Chan, Noel C / Weitz, Jeffrey I

    European heart journal

    2022  Volume 43, Issue 10, Page(s) 993–995

    MeSH term(s) Anticoagulants/therapeutic use ; Anticoagulation Reversal ; Arginine/analogs & derivatives ; Humans ; Piperazines
    Chemical Substances Anticoagulants ; Piperazines ; Arginine (94ZLA3W45F) ; PER977 (U2R67KV65Q)
    Language English
    Publishing date 2022-06-23
    Publishing country England
    Document type Editorial ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 603098-1
    ISSN 1522-9645 ; 0195-668X
    ISSN (online) 1522-9645
    ISSN 0195-668X
    DOI 10.1093/eurheartj/ehab706
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1563: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 640: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: What Is the Future of Factor XI Inhibitors?

    Weitz, Jeffrey I / Eikelboom, John W

    Circulation

    2022  Volume 146, Issue 25, Page(s) 1899–1902

    MeSH term(s) Humans ; Factor XI ; Anticoagulants/therapeutic use ; Atrial Fibrillation/drug therapy ; Administration, Oral ; Stroke/drug therapy ; Factor Xa Inhibitors/therapeutic use
    Chemical Substances Factor XI (9013-55-2) ; Anticoagulants ; Factor Xa Inhibitors
    Language English
    Publishing date 2022-12-19
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80099-5
    ISSN 1524-4539 ; 0009-7322 ; 0069-4193 ; 0065-8499
    ISSN (online) 1524-4539
    ISSN 0009-7322 ; 0069-4193 ; 0065-8499
    DOI 10.1161/CIRCULATIONAHA.122.061132
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui IV Zs.60: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top